Kiniksa Pharmaceuticals International, plc (KNSA)
| Market Cap | 7.48B +157.2% |
| Revenue (ttm) | 945.96M +58.2% |
| Net Income | 109.57M +205.1% |
| EPS | 1.32 +183.6% |
| Shares Out | 78.57M |
| PE Ratio | 71.92 |
| Forward PE | 50.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 419,007 |
| Open | 97.35 |
| Previous Close | 98.76 |
| Day's Range | 94.03 - 98.37 |
| 52-Week Range | 37.02 - 99.31 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 109.43 (+14.95%) |
| Earnings Date | Oct 27, 2026 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $109.43, which is an increase of 14.95% from the latest price.
News
Kiniksa price target raised to $122 from $107 at JPMorgan
JPMorgan raised the firm’s price target on Kiniksa (KNSA) to $122 from $107 and keeps an Overweight rating on the shares.
Kiniksa price target raised to $101 from $90 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Kiniksa (KNSA) to $101 from $90 and keeps a Buy rating on the shares. Kiniksa delivered a strong Q3 beat-and-raise, with Arcalyst…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q3 2026
Q3 ARCALYST revenue grew 58% YoY to $286M, and 2026 sales guidance rose to $1.045B-$1.050B. Development advanced for KPL-387 and KPL-1161, with KPL-387 pivotal data expected in H2 2027.
Kiniksa Pharmaceuticals International, Earnings release: Q3 2026
Kiniksa Pharmaceuticals International, released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Kiniksa Pharmaceuticals International, Slides: Q3 2026
Kiniksa Pharmaceuticals International, has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Kiniksa Pharmaceuticals International, Quarterly report: Q3 2026
Kiniksa Pharmaceuticals International, has published its Q3 2026 quarterly earnings report on October 27, 2026.
Kiniksa reports Q3 EPS 56c, consensus 31c
Reports Q3 revenue $285.97M, consensus $260.61M. “Kiniksa (KNSA) continues to build a leading IL-1alpha and IL-1beta inhibition franchise, driven by the commercialization of ARCALYST in recurrent peri...
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – –...
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at...
Kiniksa Pharmaceuticals International, Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw record revenue growth and increased 2026 guidance, with ARCALYST showing strong market expansion and significant untapped potential. Pipeline assets KPL-387 and KPL-1161 are advancing, supported by robust clinical data and strategic focus on innovation, patient access, and long-term value.
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual ...
Kiniksa Pharmaceuticals International, Transcript: Canaccord Genuity's 46th Annual Growth Conference
ARCALYST continues to drive strong revenue growth and market penetration in recurrent pericarditis, with patients typically remaining on therapy for a median of three years. The company is advancing its pipeline with KPL-387 in phase III and expanding outreach through targeted education and DTC campaigns.
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th An...
Kiniksa price target raised to $90 from $75 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Kiniksa (KNSA) to $90 from $75 and keeps a Buy rating on the shares. Kiniksa delivered another beat-and-raise quarter,…
Kiniksa price target raised to $99 from $72 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $99 from $72 and keeps an Outperform rating on the shares. The firm notes the company reported positive recurrent pericarditis…
Kiniksa price target raised to $107 from $72 at JPMorgan
JPMorgan raised the firm’s price target on Kiniksa (KNSA) to $107 from $72 and keeps an Overweight rating on the shares.
Kiniksa price target raised to $98 from $64 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Kiniksa (KNSA) to $98 from $64 and keeps a Buy rating on the shares. The firm updated its model following…
Kiniksa price target raised to $100 from $60 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $100 from $60 and keeps a Buy rating on the shares. The firm views the company’s Q2…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q2 2026
Q2 2026 saw ARCALYST revenue surge 55% year-over-year to $243.6 million, driving a guidance raise to $980–995 million for the year. The pivotal phase III trial for KPL-387 began enrollment, supported by strong phase II data, while cash reserves grew to $525.9 million.
Kiniksa Pharmaceuticals International, Earnings release: Q2 2026
Kiniksa Pharmaceuticals International, released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Kiniksa Pharmaceuticals International, Slides: Q2 2026
Kiniksa Pharmaceuticals International, has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.